

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited

華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

TERMINATION OF CONNECTED TRANSACTION IN RELATION TO THE WITHDRAWAL AS A LIMITED PARTNER FROM THE FUND

Reference is made to the announcement of China Resources Medical Holdings Company Limited (the “**Company**”) dated September 19, 2019 (the “**Announcement**”) in relation to the entering into of the subscription agreement by Unison Champ Premium Limited (formerly known as Unison Champ Limited, which is a wholly-owned subsidiary of the Company, “**Unison Champ**”) in respect of the interest in CMH Healthcare Fund, L.P. (the “**Fund**”) as a limited partner. Unless otherwise defined in this announcement, the capitalised terms used herein shall have the same meanings as those defined in the Announcement.

At the date of this announcement, CR Healthcare (which is a wholly-owned subsidiary of CR Holdings) holds 35.76% of the issued shares of the Company and is the Company’s single largest shareholder and controlling shareholder (as ascribed under the Listing Rules), while the General Partner is held 40% by CRHFM (Cayman) (which is also a wholly-owned subsidiary of CR Holdings), and the General Partner is therefore a connected person of the Company by virtue of being an associate of our controlling shareholder. The withdrawal of the Fund is subject to the announcement requirement under Rule 14A.35 of the Listing Rules.

As disclosed in the Announcement, on September 19, 2019, Unison Champ and General Partner entered into the Subscription Agreement in relation to the former's investment to the Fund. Pursuant to the Subscription Agreement, the proposed capital commitment of Unison Champ amounted to US\$40 million (equivalent to approximately RMB285 million), and the Fund intended to raise a total of US\$1 billion. Unison Champ has also appointed the General Partner as its attorney to sign the LP Agreement on its behalf.

The Board hereby announces that on February 14, 2022, Unison Champ and the General Partner entered into a letter agreement (the "**Withdrawal Letter**"), pursuant to which Unison Champ requested the General Partner to consent to its withdrawal as a Limited Partner in whole from the Fund (the "**Withdrawal**") and cancellation of its entire interests in the Fund (the "**Cancellation of Interests**") and the General Partner has given its consent to the Withdrawal and the Cancellation of Interests. With effect from the date of the Withdrawal Letter: (i) the General Partner will effectuate the Withdrawal and the Cancellation of Interests pursuant to the relevant clause as set out in the LP Agreement; (ii) Unison Champ will cease to be a Limited Partner and will no longer be entitled to any rights of a Limited Partner under the LP Agreement; and (iii) the General Partner will have no claims or rights of whatsoever kind against Unison Champ, and not make further drawdowns from Unison Champ.

The Fund has not made any investment, and accordingly, no distribution and/or other proceeds has been made or distributed to its investors. As of the date of the Withdrawal Letter, other than the debts and liabilities already incurred and owed by the Fund to third party service providers and agents, there is no unliquidated debts and liabilities of the Fund. Pursuant to the Withdrawal Letter, Unison Champ shall not be liable to any expenses, costs or fees incurred exceeding its capital contribution in accordance with the proportion of capital commitment to the Fund amounted to US\$617,933. Unison Champ's capital contribution which has not been used in the amount of US\$45,091 (the "**Contribution to be returned**") will be returned by the General Partner to Unison Champ within 30 days upon the date of the Withdrawal Letter. Except for the amount of the Contribution to be returned, there is no other distribution or payment due and payable by the Fund to Unison Champ and no other liabilities and obligations owed to the Unison Champ by the Fund, and Unison Champ is not entitled to any other payment from the assets of the Fund in respect of the Withdrawal and/or the Cancellation of Interests.

The Company has considered that the Fund has not made any investment since its establishment mainly due to the impacts of COVID-19 pandemic; and according to the Company's "14th Five-Year" strategy, the development direction of the Fund is considered not aligned with the Company's core business and not able to have synergy. Taking into account the mentioned factors, the Company therefore decided to withdraw as a Limited Partner from the Fund.

Save as disclosed above, upon the Withdrawal and Cancellation of Interest, there are no other outstanding debts and liabilities between the parties of the Subscription Agreement and the LP Agreement, nor are there any disputes or controversies relating to the arrangement thereunder. The Board considers that the Withdrawal and Cancellation of Interest are in the interests of the Company and its Shareholders as a whole and has no material adverse impact on the business, operation or financial condition of the Group.

By Order of the Board of
China Resources Medical Holdings Company Limited
CHENG Libing
Executive Director and Chief Executive Officer

Beijing, February 14, 2022

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. CHENG Libing, Ms. REN Yuan and Mr. SHAN Baojie as executive Directors; Mr. HU Hui as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Ms. CHIU Kam Hing Kathy and Mr. LEE Kar Chung Felix as independent non-executive Directors.